Evidence of inconsistencies that hinder scientific progress and harm taxpayers and cancer patients
Shorter version for policymakers about inconsistencies hurting us: https://bit.ly/4fsbXIl
Longer version for scientists and reviewers about inconsistencies hurting us: https://bit.ly/4fscbzb
Video: Crosetto’s Two-Hour Presentation
Slides: 102 Presentation Slides
Six Articles: Two-Page Articles with References
Crosetto Foundation for the Reduction of Cancer Deaths Welcomes Transparency in Science
Italian-American scientist Dario Crosetto expresses his heartfelt gratitude to the IEEE-NSS-MIC-RTSD General Chair and Conference Program Chairs for their support of transparency in science.
All six of Crosetto’s articles were accepted for presentation at the world’s premier conference on particle physics and medical imaging, held in Tampa, Florida, and attended by over 1,300 scientists. Crosetto was allocated nearly two hours—the longest presentation at the conference—to present 102 slides detailing the transformative capabilities of his 3D-Flow and 3D-CBS inventions compared to existing technologies. These inventions have the power to revolutionize both particle detection and cancer screening, offering unmatched performance and cost-efficiency.
The titles of his six articles appear in the N-29 Session of the conference program (later renamed WS-29 on the website but still referenced as N-29 in official documents), each accompanied by a two-page summary and references accepted by reviewers.
IEEE is the world’s largest technical professional organization, with over 409,000 members dedicated to advancing technology for the benefit of humanity.
Challenges with Transparency and the Restoration of Presentation
Out of respect and gratitude for the IEEE leaders who supported transparency in science and approved his articles, Crosetto sent a copy of his slides to all Chairs of the IEEE-NSS-MIC-RTSD Conference in advance of his public presentation at the IEEE Conference on 31 October 2024. He invited their feedback, asking if there was anything illegitimate, non-scientific, or non-compliant that required removal. The General Chair acknowledged this gesture with thanks for his courtesy but assured him that it was not necessary to send the slides before the presentation.
Crosetto’s prudence and respect were well-founded. Twenty-one days after his presentation, during which his video and slides were made publicly available to all participants, the IEEE General Chair unexpectedly changed the session’s URL link from “N-29” (https://bit.ly/3XtFJps) to “WS-29” (https://bit.ly/4fktS3Y), making access more difficult. Additionally, the video and slides were removed from the IEEE conference website, citing concerns about HIPAA and Privacy Act of 1974 privacy regulations related to Crosetto’s disclosure of his basal cell carcinoma and his partner’s undetected multiple tumors, which had grown to sizes of 10 to 14 cm over nearly ten years before symptoms appeared.
Crosetto and his partner immediately provided formal written consent for the release of their medical information, enabling reinstatement of the video. Fourteen days later, the IEEE General Chair restored the video, making it publicly accessible to all participants for an additional four days before all conference materials were removed. Communications with IEEE Conference Chairs is available at (https://bit.ly/49GB6hm) and consent documentation can be accessed (https://bit.ly/3DlC7PR).
The Responsibility of Science: Transparency and Disseminating Life-Saving Innovations
On 25 November 2024, after the General Chair of the IEEE-NSS-MIC-RTSD Conference postedCrosetto’s twohour video and slides publicly to all participants for 21 days, he stated in an email to Crosetto and other IEEE leaders: “All interested attendees were at your talk,” and notably, no one refuted Crosetto’s claims.
Although the conference was attended by scientists from Europe, Japan, the United States, and many other countries, his presentation has not yet reached key decision-makers, including global leaders and reviewers responsible for allocating the annual $2 trillion in R&D funding. Crosetto’s groundbreaking demonstration of inventions capable of saving millions of lives and billions of dollars requires far broader dissemination.
Transparency in science is not merely an ethical obligation—it is essential for accelerating progress. Cancer patients, taxpayers, and humanity at large deserve fair access to innovations like Crosetto’s, work which represents a transformative step forward in both particle detection and cancer screening, offering tools that have the potential to revolutionize these fields.
The stakes are too high to ignore. Let us ensure that the world has the opportunity to evaluate these breakthroughs and act on their immense potential for saving lives.
A Global Call for Scientific Integrity, Justice, and Fairness to Science and Society
Key stakeholders who should urgently review Dario Crosetto’s work include decision-makers from leading funding agencies, such as the U.S. Department of Energy (DOE), National Institutes of Health (NIH), National Science Foundation (NSF), CPRIT, and European entities like the European Commission, HORIZON, BECA, and ATTRACT. These agencies and others, which have collectively allocated over $30 trillion in R&D funds since Crosetto’s invention—must either refute Crosetto’s claims or allocate a small portion of R&D funds to construct two 3D-CBS devices. These devices could save over 260 lives annually per device, potentially halving global cancer deaths and costs. Scaling the number of devices to the population this equates to 90,000 lives saved annually in Italy, 350,000 in the U.S., 700,000 in Europe and over 5 million globally.
The True Focus of the Scientific Community: Advancing Knowledge for the Greater Good
The scientific community’s priority should be advancing knowledge and fostering collaboration to benefit society. Cancer—not a colleague—is the adversary. Crosetto’s presentation and slides should undergo rigorous comparison against other funded projects. This review should not only be conducted publicly by funding agency reviewers but also by scientists who have received significant R&D funding over the past three decades. Their results should be measured against the detailed demonstrations of the outcomes Crosetto’s inventions could achieve, as presented at the IEEE Conference on October 31, 2024.
The Pillars of Innovations Fostering Progress: Honesty and Scientific Integrity
The IEEE’s stated mission is to foster technological innovation and excellence for the benefit of humanity, which was highlighted also in a letter to Crosetto from the 2019 IEEE Presidente and CEO, Dr. José Moura (https://bit.ly/2Iw40pG) stating: “As an international organization operating in 160 countries, IEEE supports the free and open exchange of scholarly and academic work and the global advancement of science and technology. IEEE is committed to enabling an environment of international cooperation and the sharing of our members’ wealth of knowledge to drive innovation”.
Upholding this mission requires honesty and scientific integrity as non-negotiable principles. When these principles are respected, scientists who have received significant funding must acknowledge the inefficiency and high costs of traditional ASIC and FPGA approaches for Level-1 Trigger in particle detection. They must also admit the failure of past projects that have not demonstrated measurable reductions in cancer deaths and costs in a specific territory where the efficacy of their project is being tested.
Evidence points to Crosetto’s 1992 3D-Flow invention, validated in a major public review in 1993, and his 2000 3D-CBS invention, which focuses on 400 times improved efficiency for lower-dose radiation and lower-cost cancer screening, as superior alternatives. In fairness to taxpayers and cancer patients, these scientists should endorse funding for Crosetto’s inventions, granting him the same opportunity to implement his ideas that they were afforded for theirs. Selectively copying ideas and features from his work without proper citation undermines not only fairness but also the integrity of scientific advancement.
Acknowledging Evidence: A Responsibility Beyond Justice
Scientists must prioritize collaboration and integrity over personal or institutional biases. Acknowledging the inefficiencies of past approaches and endorsing more effective alternatives is not just a matter of fairness, but an essential step toward advancing science and improving the quality of life for humanity.
For example, the planned 2026 CERN-LHC experiments upgrade, which intends to implement a Level-1 Trigger using FPGA technology, is projected to be both expensive and inefficient. This approach risks wasting billions of taxpayer dollars on a less effective solution compared to Crosetto’s 3D-Flow architecture, which demonstrates a more efficient alternative.
If Crosetto were given the opportunity to repeat the lecture he delivered 34 years ago at CERN in 1990 at the School of Computing (https://bit.ly/3h2IjLB) and update it with current and future technologies, he could compare various processor architectures (See Slide 4) and demonstrate that solutions such as RISC, CISC, DSP, microcontrollers, embedded controllers, GPUs, hypercubes, ARM, PowerPC, TriCore, MIPS, and even FPGAs cannot meet the stringent requirements of executing complex real-time pattern recognition algorithms on ultra-high data streams.
Crosetto has extensively tested FPGAs from three different manufacturers to validate the feasibility and functionality of his 3D-Flow invention. However, he discovered that while a 3D-Flow processor costs just $1, FPGA chips cost thousands of dollars and still fail to meet Level-1 trigger requirements.
FERMILAB recognized the revolutionary advantages of the 3D-Flow architecture, giving Crosetto the opportunity to present it during a major international public scientific review. In their report (goo.gl/zP76Tc), they acknowledged that the 3D-Flow architecture could execute Level-2 trigger algorithms at Level-1. On page 6, the report states: ‘…given this feature, experimenters would probably think of clever uses not now possible. Better Level-1 triggering will reduce the data rate into Level-2. If a large enough reduction could be achieved, Level-2 triggers could be replaced by a processor farm. It is possible the farm is the same as used for final event processing before storage.’
If CERN provided Crosetto with a similar opportunity to deliver a lecture on computer architectures, the scientific community as a whole could benefit greatly from his insights.
By fostering a culture of transparency and accountability, the scientific community can ensure that efforts are directed toward advancements that truly serve the greater good, ultimately saving millions of lives and reducing the economic burden of diseases like cancer.
The Superiority of Crosetto’s Inventions
Dario Crosetto’s groundbreaking inventions have demonstrated clear superiority in flexibility, performance, and cost-effectiveness when compared to all current and past projects in the fields of particle physics and cancer detection.
1. For Particle Physics:
- The 3D-Flow processor and system architecture (see Slide 4) offers a revolutionary approach to data processing, capable of executing over 800 programmable operations per data set arriving every 25 nanoseconds. This far surpasses the 66 operations performed by current FPGA-based systems.
- By analyzing data with greater precision, the 3D-Flow system significantly enhances the detection of new particles, reducing both costs and time, while increasing discovery potential.
2. For Cancer Detection:
- The 3D-CBS technology enables the detection of tumors with as few as 100 cancer cells with a 2- minute $200, safe screening test covering all organs of the body as compared to the 1,000,000 cells required for detection by CT, MRI, or mammograms
- This breakthrough capability allows for life-saving early interventions and drastically reduces diagnostic costs, making cancer screening affordable and accessible to the broader population.
Summary of the Inconsistencies Highlighted in Crosetto’s 102 Slides
Crosetto’s 102-slide presentation (available at https://bit.ly/3CcBqYw) reveal critical inconsistencies in particle physics and cancer detection fields that have been ignored or suppressed for three decades and need urgent resolution:
1. Particle Physics Inconsistencies
- Current Level-1 Trigger systems rely on expensive FPGA technology that executes only 66 operations every 100 ns. Crosetto’s 3D-Flow system can perform up to 800 programmable operations on each data set arriving every 25 ns at a fraction of the cost.
- In 2012, FPGA-based systems detected just 40 Higgs boson-like events out of 1,000,000 generated by the LHC, an inefficient FPGA Level-1 Trigger discarded in 2016.
- Planned FPGA-based upgrades for the 2026 CERN-LHC experiments are similarly flawed, while Crosetto’s 3D-Flow system offers superior performance, proven feasibility, and cost-efficiency. This inconsistency also emerged from the discussion between Crosetto of the keynote speaker of paper NP-01-04 and her mentors (https://bit.ly/3BmnPOt).
2. Cancer Detection Inconsistencies
- Crosetto’s 3D-CBS (PET/CT) system detects tumors with 100 cancer cells—long before the 1,000,000 cells required by CT, MRI, or mammograms.
- Despite its life-saving potential, funding has favored less efficient devices like the EXPLORER (PET/CT), which focuses on producing images for conferences rather than saving lives.
- Crosetto’s 3D-CBS system offers a 2-minute, $200 screening for early cancer detection, saving over 260 lives annually per device.
Detailed Inconsistencies Highlighted in Crosetto’s 102 Slides (available at https://bit.ly/3CcBqYw).
1. Particle Physics Inconsistencies
1a) Despite the 1992 3D-Flow solution for Level-1 Trigger (Slides 6–8), which was officially recognized in 1993 (Slide 20) to have the capability to execute Level-2 algorithms without missing any data arriving every 25 ns, the scientific community eliminated Level-2 Trigger functionality (Slide 5) without having a hardware solution capable to execute Level-2 algorithms at Level-1, instead renaming Level-2 as Level-1 Trigger.
1b) In 1999, High Energy Physics (HEP) took a wrong turn by using ASICs and FPGAs (Slide 23), which lacked the capability to execute complex algorithms while sustaining a 40 MHz input data rate.
1c) A 1999 peer-reviewed article (Slides 21–22) demonstrated that 3D-Flow could execute Level-1 programmable algorithms with over 400 operations on each data set arriving every 25 ns, without missing any data. This outperforms the less than 40 operations achieved by FPGA-based Level-1 systems.
1d) In 2012, FPGA-based Level-1 Trigger systems detected only 40 Higgs boson-like events out of 1,000,000 generated by the LHC (Slides 26–27). These systems were deemed ineffective and were discarded by 2016 (reference in Slide 23).
1e) The 3D-Flow proposal (Slide 27), supported by 59 quotes, demonstrated the feasibility of replacing an entire room of FPGA-based Level-1 electronics costing 1,000 times more than one VXI crate 3D-Flow system with 8,192 electronic channels detailed in Slides 34–46.
1f) Despite this evidence, HEP took another wrong turn in 2023 (Slide 28) continuing to stick with FPGA systems incapable of executing complex Level-1 algorithms while sustaining a 40 MHz input data rate.
1g) Crosetto’s summary (Slide 47) and discussions with the keynote speaker (NP-01-04) and her mentors (https://bit.ly/3BmnPOt) revealed that the very expensive CERN Level-1 Trigger for the 2026 LHC experiments upgrade with FPGAs is limited to 100 ns and 66 operations, while Crosetto’s 3D-Flow system can execute up to 800 operations on each data set arriving every 25 ns, at a fraction of the cost and without missing any data.
2. Cancer Detection Inconsistencies
2a) Despite the 2000 3D-CBS solution for cost-effective early cancer detection to save many lives and reduce healthcare costs, which focuses on measuring bio-physiology (Slides 53, 57, 65–66), the medical imaging community took a wrong turn in 1998 (Slide 79).
2b) This misdirection, confirmed by industry in 2002 (Slide 54), was perpetuated by funding agencies directing resources toward less effective approaches (Slide 61). A 2016 study on 100,000 patients demonstrated these approaches did not save lives (Slide 89).
2c) In 2003, Crosetto proved in FPGA hardware modular boards, feasibility and functionality of his 3D-Flow system for detectors of any size in both HEP and 3D-CBS medical imaging applications (Slide 26).
2d) In 2015, Crosetto demonstrated feasibility supported by 59 quotes, to build the 3D-CBS device focused on measuring bio-physiology, targeted to both, research and save many lives with components costing less than $2 million per device and an estimated sale price of $3.5 million per device (Slides 67–69).
2e) Meanwhile, hundreds of millions of dollars were invested in the less efficient EXPLORER device, which focuses on producing beautiful pictures (Slides 80–82). This device, targeted mainly for research and NOT suitable for saving many lives, is sold commercially for $21 million per device (Slide 70).
2f) In 2017, Crosetto provided a detailed study of the operating cost of the 3D-CBS at $200 per 2-minute screening test and $1,200 per 15-minute clinical workup (Slides 71–73), demonstrating to save over 260 lives per 3D-CBS device per year (Slide 74), with the potential to save over 90,000 lives annually in Italy and over 5 million lives saved globally per year (Slides 75, 90).
2g) Independent measurements over two decades have validated Crosetto’s patented invention, as others who copied his ideas and features confirmed its accuracy (Slides 83–88).
2h) Crosetto’s personal case of his tumor, fortunately detected early by his dermatologist, and the case of his partner’s delayed diagnosis due to undetected tumors for up to 10 years underscores the critical importance of early detection (Slides 93–94).
2i) The 3D-CBS and 3D-Flow systems demonstrate the highest potential to reduce cancer deaths and costs when compared to liquid biopsies and other cancer screening procedures (Slides 95–98).
2j) A test on the EXPLORER device, performed after Crosetto’s diagnosis, revealed that the device prioritizes creating dynamic images for conferences over providing essential bio-physiological measurements, which are crucial for patients (Slides 99–101). When Crosetto was diagnosed with a tumor, before removing it, he underwent an exam on the EXPLORER device. He wanted to know more about the biophysiology of his tumor, testing the sensitivity of the machine and how the device could help patients. However, the test revealed the inconsistency that the device and software are designed for research and to show astonishing results at conferences to receive more funding to fuel the cancer business, without providing essential information to the patient on measurements of the bio-physiology of cancer cells compared to surrounding cells, as happened to Crosetto, who is still waiting for this information one year after he underwent the test on the EXPLORER on 1 December 2023.
2k) Slide 100 highlights the staggering inconsistency in claims of reduced cancer deaths. For example, breast cancer deaths in Italy increased from 12,760 in 2016 to 15,500 in 2022, despite claims of improvement. Slide 102 further illustrates the inconsistency of a higher cost of the private healthcare system providing less benefits to the public than a lower cost public healthcare system. For example, with Italy achieving with a public healthcare system a higher average life expectancy (84 years) at a third of the cost compared to the U.S. private healthcare system (79 years). However, Italian policymakers risk replicating the U.S. system, which prioritizes profits over patient care, if they continue to ignore long waiting lists that are forcing patients toward a private healthcare system. A significant share of the responsibility for the inconsistency between high healthcare costs and meager benefits to taxpayers and cancer patients in reducing premature cancer deaths, whether on private or public healthcare systems, lies with scientists. These scientists prioritize creating instrumentations and drugs to fuel the cancer business rather than serving the interest of taxpayers and cancer patients. A significant example is Crosetto’s 3D-CBS invention targeted to a cost-effective, safe, low-radiation, low-cost cancer screening for early cancer detection to save lives. While funding has been allocated to implement instrumentation primarily for research and developing new drugs, this approach is unsuitable for saving many lives. Crosetto 3D-CBS went unfunded, and for over a year, he has been waiting for the measurements from the EXPLORER device that shows the bio-physiology of his cancer cells compare to the surrounding healthy tissue.
A Call to Action for Funding and Experimental Validation
Despite suppression for three decades, Crosetto’s inventions remain unrefuted. Institutions must fund experimental validation of the 3D-Flow and 3D-CBS systems to confirm their transformative potential.
A Proactive Public Challenge
Out of respect for all institutions, policymakers, leaders, and scientists who may be connected to the facts, truths and findings presented in Crosetto’s two-hour talk, and even more so for the over 9 billion people worldwide who stand to benefit from a scientific breakthrough capable of reducing suffering and economic burdens for current and future generations, Crosetto has taken a proactive approach.
As in previous instances, in this spirit, he is submitting his video (https://youtu.be/9pScoT46KhY), slides (https://bit.ly/3CcBqYw), and articles (https://bit.ly/3Nu6e9u) to global leaders, scientists, and policymakers listed in Appendix B (https://bit.ly/3VEDcsg) of this letter. He invites them to identify any illegitimate, nonscientific, or non-compliant statements in his oral or written materials that would warrant reconsideration or removal. (Please feel free to forward this letter to other relevant scientists and policymakers who may not yet be on Appendix B).
Crosetto and his partner firmly believe that the immense benefits of his inventions to humanity—providing powerful tools for particle discovery, advancing science, and halving cancer deaths and costs—far outweigh any concerns about the privacy of their medical information. This belief aligns with the same selflessness as individuals who choose to donate their organs upon death to benefit others.
Prioritizing transparency and public welfare, both Crosetto and his partner have entirely addressed the privacy concerns by signing a broad consent form, allowing unrestricted public dissemination of the medical information included in Crosetto’s presentation, slides, and articles (See Appendix A https://bit.ly/3DlC7PR). Additionally, Crosetto has made publicly available the 1.63 GB of data from his PET/CT EXPLORER exam conducted on 1 December 2023, at BAMF in Grand Rapids, Michigan (link to CD: https://bit.ly/49EmxuR).
A Civilizational Responsibility
Crosetto’s work represents a pivotal moment for humanity. Transparency, fairness, and justice demand that this revolutionary technology be given the opportunity to prove its merits through experimental results. The potential to save lives and transform both scientific and medical practices is too great to ignore.
The Urgency of Action
The time to act is now. Together, we can build a world where cancer is detected early, and lives are saved. Without immediate support, millions of lives that could be saved will continue to be lost. It is imperative to fund the experimental validation of Crosetto’s inventions. The potential impact of 3D-Flow and 3D-CBS is unprecedented—not only in advancing particle physics and medical imaging but also in transforming the global fight against cancer.
For every second that passes, countless lives are at risk. It’s time to act, to innovate, and to embrace a future where early cancer detection and cost-effective healthcare become reality.
Next Steps: Public Transparency, Debate and Collaboration
Following this respectful communication with scientists and policymakers, Crosetto plans to make his findings widely available. Open public discussion will ensure that his ideas are compared transparently to alternatives, fostering collaboration and accountability.
The failure to adopt 3D-Flow and 3D-CBS technologies earlier has already wasted resources and lives. Moving forward, embracing and funding experimentation of Crosetto’s inventions is essential for fulfilling ethical and professional obligations to taxpayers and cancer patients worldwide.
Sincerely,
Dario Crosetto
President of the Crosetto Foundation for the Reduction of Cancer Deaths
Email: crosettodario@gmail.com
